Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Listen to this summary
This study aimed to evaluate the efficacy of once-weekly semaglutide in reducing heavy drinking days among treatment-seeking patients with alcohol use disorder and comorbid obesity. The results demonstrated that semaglutide significantly reduced heavy drinking days compared to placebo, supporting its potential as a novel therapeutic intervention for alcohol use disorder. Additionally, the treatment was generally well-tolerated, with mild to moderate gastrointestinal side effects reported more frequently in the semaglutide group.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →May 10, 2026 · Lancet (London, England)
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
May 10, 2026 · Lancet (London, England)
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
May 10, 2026 · Lancet (London, England)
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
May 9, 2026 · Lancet (London, England)
The role of community-based blood pressure screening in improving hypertension care
May 8, 2026 · Lancet (London, England)
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial
May 3, 2026 · Lancet (London, England)
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
More in Nuclear Medicine
View all →May 6, 2026 · The New England journal of medicine
Daraxonrasib in Previously Treated Advanced <em>RAS</em>-Mutated Pancreatic Cancer
May 6, 2026 · The New England journal of medicine
Cerebral Amyloid Angiopathy
May 6, 2026 · The New England journal of medicine
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
May 6, 2026 · The New England journal of medicine
Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies
Apr 29, 2026 · The New England journal of medicine
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Apr 29, 2026 · The New England journal of medicine
Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
